 
在美國，'''藥物福利管理者'''（{{lang-en|pharmacy benefit manager}}，PBM）是{{link-en|第三方管理者| third-party administrator}}，為商業醫療保險計劃、雇主自辦保險計劃、[[聯邦醫療保險D部分|聯邦醫療保險D部分]]計劃、{{link-en|聯邦僱員醫療福利計劃|Federal Employees Health Benefits Program}}、和州政府僱員醫療福利計劃，負責管理[[處方藥|處方藥]]的保險計劃。<ref name=":0">{{cite web|url=http://qz.com/636823/big-pharmacies-are-dismantling-the-industry-that-keeps-us-drug-costs-even-sort-of-under-control/|title=Big pharmacies are dismantling the industry that keeps US drug costs even sort-of under control|last=Feldman|first=Brian S.|website=Quartz|date=|access-date=2016-03-29|archive-date=2020-11-12|archive-url=https://web.archive.org/web/20201112023851/https://qz.com/636823/big-pharmacies-are-dismantling-the-industry-that-keeps-us-drug-costs-even-sort-of-under-control/|dead-url=no}}</ref><ref>{{Cite news|url=https://www.wsj.com/articles/SB10001424053111903554904576460322664055328|title=What is a 'Pharmacy Benefit Manager?'|last=Gryta|first=Thomas|newspaper=Wall Street Journal|issn=0099-9660|access-date=2016-03-29|archive-date=2020-10-15|archive-url=https://web.archive.org/web/20201015222254/https://www.wsj.com/articles/SB10001424053111903554904576460322664055328|dead-url=no}}</ref>根據[[美國藥劑師協會|美國藥劑師協會]]的說法，「PBM主要負責的是在[[處方集|處方集]]的開發和維護，與藥房簽約、與藥廠議定折扣和回扣、以及為處方藥的理賠作處理和支付。」<ref name="APhA_2009">{{cite web | url=https://www.pharmacist.com/sites/default/files/files/Profile_24_PBM_SDS_FINAL_090707.pdf | title=Pharmacy Benefit Management | work=American Pharmacists Association | date=July 9, 2009 | accessdate=November 4, 2015 | archive-date=2020-09-26 | archive-url=https://web.archive.org/web/20200926044155/https://www.pharmacist.com/sites/default/files/files/Profile_24_PBM_SDS_FINAL_090707.pdf | dead-url=no }}</ref><ref name=":2">{{cite web|url=http://www.dol.gov/ebsa/pdf/acdanzon061914.pdf|title=2014 ERISA Advisory Council: PBM Compensation and Fee Disclosure|last=Danzon|first=Patricia|date=June 29, 2014|website=|publisher=|access-date=2016-03-29|archive-date=2016-08-17|archive-url=https://web.archive.org/web/20160817033545/https://www.dol.gov/ebsa/pdf/ACDanzon061914.pdf|dead-url=no}}</ref>PBM在綜合醫療衛生機構內部運作（例如{{link-en|凱撒醫院|Kaiser Permanente}}，或是{{link-en|美國退伍軍人醫療管理局|Veterans Health Administration}}），本身是零售藥房系統的一部分（例如[[CVS藥局|CVS藥局]]，或是[[來愛德|來愛德]]）、或者是保險公司的一部分（例如[[聯合健康集團|聯合健康集團]]）。<ref name=":0" /><ref name=":2" />

截至2016年，PBM為美國管理藥物福利，覆蓋的人數達到2.66億人。2017年，美國規模最大的PBM公司，收入比最大的藥廠還高，表明這個類別的產業在美國[[醫療系統|醫療系統]]中的角色越來越重要。<ref name="SchulmanRichman2018">{{cite journal|last1=Schulman|first1=Kevin A.|last2=Richman|first2=Barak D.|title=The Evolving Pharmaceutical Benefits Market|journal=JAMA|volume=319|issue=22|year=2018|pages=2269|issn=0098-7484|doi=10.1001/jama.2018.4269}}</ref>值得注意的是在2016年，美國主要的PBM公司數目少於30個，<ref name="SchulmanRichman2018">{{cite journal|last1=Schulman|first1=Kevin A.|last2=Richman|first2=Barak D.|title=The Evolving Pharmaceutical Benefits Market|journal=JAMA|volume=319|issue=22|year=2018|pages=2269|issn=0098-7484|doi=10.1001/jama.2018.4269}}</ref>其中三個最大的（[[快捷藥方|快捷藥方]]、CVS藥局、和聯合健康集團中的OptumRx），它們共同的市場佔有率是78％，為1.8億登記加入者提供覆蓋。<ref name=":0" /><ref name=":3">{{cite web|url=https://judiciary.house.gov/wp-content/uploads/2016/02/Balto-Testimony-1.pdf|title=The State of Competition in the Pharmacy Benefits Manager and Pharmacy Marketplaces|last=Balto|first=David A.|date=November 17, 2015|website=|publisher=House Judiciary Subcommittee on Regulatory Reform, Commercial, and Antitrust Law|access-date=2016-03-29|archive-date=2018-09-24|archive-url=https://web.archive.org/web/20180924233527/https://judiciary.house.gov/wp-content/uploads/2016/02/Balto-Testimony-1.pdf|dead-url=no}}</ref>。

==商業模式==
在美國，醫療保險公司通常僱用第三方的管理者，協助處理藥物價格談判、保險理賠、和處方藥的配送。會運用到這種管理者的機構包括商業醫療保險計劃、雇主自辦保險計劃、聯播按醫療保險D部分計劃、聯邦僱員醫療福利計劃、和州政府僱員醫療福利計劃。<ref name=":0"/>PBM被設計成利用登記加入者的醫療保險計劃，把他們的集體購買力匯集，讓前述保險計劃贊助者以及個人能夠利用較低的價格獲得處方藥。PBM從零售藥房取得價格折扣，從藥廠以及郵遞藥房取得回扣，郵購藥房可在患者無須與[[藥劑師|藥劑師]]面對面諮詢的情況下，把處方藥品交付到患者住處。<ref>{{cite web|url=http://www.spcma.org/component/knowledge/?stack=34|title=Pharmaceutical Care Management Association|website=www.spcma.org|access-date=2016-03-29|archive-date=2016-04-14|archive-url=https://web.archive.org/web/20160414055605/http://www.spcma.org/component/knowledge/?stack=34|dead-url=no}}</ref>
 
藥物福利管理公司可從幾種途徑獲得收入。首先，他們從原始醫療保險計劃收取管理費和服務費。他們還可從藥廠那裡收取回扣。傳統的PBM不會披露處方藥的議定淨價格，他們得以使用高於淨價的公開標價（也稱為標籤價格（sticker price））出售藥品。<ref>{{cite web|url=https://www.pewtrusts.org/en/research-and-analysis/reports/2019/03/08/the-prescription-drug-landscape-explored|title=The Prescription Drug Landscape, ExploredA look at retail pharmaceutical spending from 2012 to 2016|publisher=Pew Charitable Trusts|date=8 Mar 2019|accessdate=12 Apr 2019|archive-date=2021-05-01|archive-url=https://web.archive.org/web/20210501065311/https://www.pewtrusts.org/en/research-and-analysis/reports/2019/03/08/the-prescription-drug-landscape-explored|dead-url=no}}</ref>這種做法被稱為"價差定價"。<ref>{{cite web|url=https://www.dispatch.com/news/20190409/bipartisan-leaders-of-senate-panel-call-for-federal-probe-of-pbms-pricing-methods|title=Bipartisan leaders of Senate panel call for federal probe of PBMs’ pricing methods|publisher=The Columbus Dispatch|author=Jack Torry|date=9 Apr 2019|accessdate=9 Apr 2019|archive-date=2021-01-20|archive-url=https://web.archive.org/web/20210120234316/https://www.dispatch.com/news/20190409/bipartisan-leaders-of-senate-panel-call-for-federal-probe-of-pbms-pricing-methods|dead-url=no}}</ref>價差數字被視為[[商業秘密|商業秘密]]。<ref>Sarpatwari A, Avorn J, Kesselheim AS. [https://jamanetwork.com/journals/jama/article-abstract/2681947 An Incomplete Prescription.President Trump’s Plan to Address High Drug Prices.] {{Wayback|url=https://jamanetwork.com/journals/jama/article-abstract/2681947 |date=20201009132308 }} JAMA. 2018;319(23):2373–2374. doi:10.1001/jama.2018.7424</ref>PBM通常禁止藥房和保險公司公開談論費用和報銷金額。這種作法導致的結果是缺乏價格透明度。

==處方集==
{{main2|[[處方集|處方集]]}} 

PBM為它們的客戶提供有關"架構藥物福利"的建議，並根據各種價格提供複雜的選擇給患者。這是透過構建醫療計劃涵蓋的"處方集"或特定藥物清單來達成。處方集通常分為幾個偏好的"階級"，階級越低的有較高的[[共付額|共付額]]，以激勵消費者購買自己偏好階級的藥品。如果藥品沒列在處方集上，就表示消費者必須支付價目表的全額價錢來購買。為了讓藥物能夠被列入處方集裡面，藥廠通常需要向PBM支付回扣，這就會把藥品的淨價降低，但是在價目表上的標價仍保持不變。<ref>{{cite web|url=http://time.com/5564547/drug-prices-medicine/|title=Why Does Medicine Cost So Much? Here's How Drug Prices Are Set|publisher=Time|author=Laura Entis|date=9 Apr 2019|accessdate=12 Apr 2019|archive-date=2021-03-25|archive-url=https://web.archive.org/web/20210325115443/https://time.com/5564547/drug-prices-medicine/|dead-url=no}}</ref> [[製藥產業|製藥產業]]中的藥廠表示，為了彌補這些回扣的成本，他們被迫提高藥品價格。例如，[[禮來公司|禮來公司]]的總裁聲稱折扣，再加上回扣的成本，佔他們公司[[胰島素|胰島素]]定價的75％。像快捷藥方之類的PBM聲稱回扣是藥廠對標價上漲的回應，而不是漲價的原因。<ref>{{cite web|url=https://nmpoliticalreport.com/2019/04/11/the-blame-game-everyone-and-no-one-is-raising-insulin-prices/|title=The Blame Game: Everyone and no one is raising insulin prices|publisher=NM political Report|author=Rachel Bluth (Kaiser Health News)|date=11 Apr 2019|accessdate=13 Apr 2019|archive-date=2021-01-28|archive-url=https://web.archive.org/web/20210128093718/https://nmpoliticalreport.com/2019/04/11/the-blame-game-everyone-and-no-one-is-raising-insulin-prices/|dead-url=no}}</ref>
 
處方集的複雜定價結構可能會生出意想不到的後果。當保險理賠被提出的時候，患者支付的共付額是根據公開標價計算，而不是根據秘密議定後的淨價。大約有四分之一的機會，患者根據標價計算出的共付額，會比直接以現金購買的藥品總價高。然後，PBM可通過稱為"{{link-en|撈回|clawback}}"的做法把差價放進自己的口袋。<ref>{{cite web|url=https://www.pbs.org/newshour/health/why-a-patient-paid-a-285-copay-for-a-40-drug|title=Why a patient paid a $285 copay for a $40 drug|publisher=PBS Newshour|author=Megan Thompson|date=19 Aug 2018|accessdate=12 Apr 2019|archive-date=2021-01-27|archive-url=https://web.archive.org/web/20210127181147/https://www.pbs.org/newshour/health/why-a-patient-paid-a-285-copay-for-a-40-drug|dead-url=no}}</ref>消費者可選擇用現金購買藥物，但PBM在與藥房簽訂的合同中，除非消費者自己直接向藥劑師提出要求，否則禁止[[藥劑師|藥劑師]]主動告知消費者不用申請保險理賠，而可用較低的價格購得藥物。<ref>{{cite web|url=https://www.npr.org/sections/health-shots/2018/05/29/614556060/to-lower-your-medicare-drug-costs-ask-your-pharmacist-for-the-cash-price|title=To Lower Your Medicare Drug Costs, Ask Your Pharmacist For The Cash Price|publisher=NPR|author=Susan Jaffe|date=29 May 2018|accessdate=12 Apr 2019|archive-date=2020-08-13|archive-url=https://web.archive.org/web/20200813095853/https://www.npr.org/sections/health-shots/2018/05/29/614556060/to-lower-your-medicare-drug-costs-ask-your-pharmacist-for-the-cash-price|dead-url=no}}</ref>自2017年以來，美國已有六個州通過立法，將此類"噤聲條款（gag clauses）"視為非法。<ref>{{cite web|url=http://www.ncsl.org/Portals/1/Documents/Health/Pharmacist_Gag_clauses-2018_14523.pdf|title=Prohibiting PBM “Gag Clauses” that Restrict Pharmacists from Disclosing Price Options  Recent State Legislation 2017-2018|publisher=National Conference of State Legislatures|archive-url=https://web.archive.org/web/20180321054851/http://www.ncsl.org/Portals/1/Documents/Health/Pharmacist_Gag_clauses-2018_14523.pdf|date=14 Mar 2018|archive-date=2018-03-21|author=Richard Cauchi|access-date=2020-10-10|dead-url=no}}</ref>隨後，聯邦政府於2018年10月<ref>{{cite web|url=https://www.cnn.com/2018/10/10/politics/drug-prices-legislation-signed-into-law-donald-trump/index.html|title=Trump signs bills aimed at increasing drug price transparency|publisher=CNN|author=Maegan Vazquez|date=10 Oct 2018|accessdate=13 Apr 2019|archive-date=2021-01-16|archive-url=https://web.archive.org/web/20210116005850/https://www.cnn.com/2018/10/10/politics/drug-prices-legislation-signed-into-law-donald-trump/index.html|dead-url=no}}</ref>禁止私人保險設有噤聲條款<ref>{{USPL|115|263}}</ref>，[[聯邦醫療保險|聯邦醫療保險]]（Medicare）也設下這種禁令，從2020年1月1日生效<ref>{{USPL|115|262}}</ref>。

===對消費者的淨影響===
總體而言，PBM的產業聲稱它們可為最終消費者節省大量成本。例如，2015年，{{link-en|CVS Caremark|CVS Caremark}}（CVS藥局的子公司）表示已將其保險計劃會員的處方藥支出，在醫療成本佔比的11.8％降至2014年的5％。<ref>{{cite web|url=http://www.prnewswire.com/news-releases/cvs-health-reports-dramatic-drop-in-prescription-drug-trend-to-5-percent-despite-rising-drug-prices-300224071.html|title=CVS Health Reports Dramatic Drop in Prescription Drug Trend to 5 Percent, Despite Rising Drug Prices|last=Health|first=CVS|website=www.prnewswire.com|access-date=2016-03-29|archive-date=2020-09-24|archive-url=https://web.archive.org/web/20200924193331/https://www.prnewswire.com/news-releases/cvs-health-reports-dramatic-drop-in-prescription-drug-trend-to-5-percent-despite-rising-drug-prices-300224071.html|dead-url=no}}</ref>但是，CVS Caremark這樣的說法存有爭議。2013年，《[[財富雜誌|財富雜誌]]》對PBM營銷做過一項調查，結果顯示：藥品定價難以解讀，客戶無從知道自己省了多少。<ref>{{cite journal|last1=Eban|first1=Katherine|title=Painful Prescription|journal=Fortune Magazine|date=October 28, 2013|archivedate=2017-05-03|archiveurl=https://web.archive.org/web/20170503065805/http://pharmacybenefitconsultants.com/site/wp-content/uploads/2013/11/Painful-Prescription-Fortune-Magazine-10-28-13.pdf|url=http://pharmacybenefitconsultants.com/site/wp-content/uploads/2013/11/Painful-Prescription-Fortune-Magazine-10-28-13.pdf|accessdate=28 January 2018|dead-url=no}}</ref>

==歷史==
1968年，Pharmaceutical Card System Inc.（這家公司後來更名為{{link-en|AdvancePCS Inc.|AdvancePCS}}）發明塑膠藥品福利卡，成立第一家PBM。<ref name=":0" />到 "1970年代，他們擔任財務中介，用書面的方式作處方藥理賠的裁定，然後到1980年代，改用電子的方式來作裁定"。<ref name="Valparaiso_2007">{{cite journal |author1=Allison Dabbs Garrett |author2=Robert Garis |title=Leveling the Playing Field in the Pharmacy Benefit Management Industry |volume=42 |number=1 |journal=Valparaiso University Law Review |pages=33–80 |date=2007 |accessdate=October 31, 2015 |url=http://scholar.valpo.edu/cgi/viewcontent.cgi?article=1131&context=vulr |archive-date=2016-09-18 |archive-url=https://web.archive.org/web/20160918055201/http://scholar.valpo.edu/cgi/viewcontent.cgi?article=1131&context=vulr |dead-url=no }}</ref>{{rp|34}}
 
到1980年代後期，"隨著醫療衛生和處方藥的成本不斷的攀升"，PBM已成為市場裡面一股重要的勢力。<ref name="cga_gov_2003">{{cite web | url=https://www.cga.ct.gov/2003/olrdata/ins/rpt/2003-R-0903.htm | title=Pharmacy Benefit Managers | publisher=Connecticut General Assembly | date=December 24, 2003 | accessdate=December 27, 2015 | author=Brierton, Janet | location=Hartford, CT | number=2003-R-0903 | archive-date=2020-09-20 | archive-url=https://web.archive.org/web/20200920082347/https://www.cga.ct.gov/2003/olrdata/ins/rpt/2003-R-0903.htm | dead-url=no }}</ref>{{link-en|多元化藥物服務|Diversified Pharmaceutical Services}}（DPS）是PBM最早的營運模式之一，最早由一家名為United HealthCare（現在稱為聯合健康集團）的全國性[[健康維護組織|健康維護組織]]所創立。<ref name="Kongstved_MHC_1995">{{cite book |title=Essentials of Managed Health Care |volume =1 |author=Peter Reid Kongstved |date=1995 |work=Barnes & Noble}}</ref>{{rp|304}}<ref name="prnewswire_1999">{{citation |url=http://www.prnewswire.com/news-releases/express-scripts-to-acquire-diversified-pharmaceutical-services-74853317.html |title=Express Scripts to Acquire Diversified Pharmaceutical Services |date=February 9, 1999 |accessdate=October 31, 2015 |location=St. Louis |work=PRNewswire |archive-url=https://web.archive.org/web/20180127202647/https://www.prnewswire.com/news-releases/express-scripts-to-acquire-diversified-pharmaceutical-services-74853317.html |archive-date=2018-01-27 |dead-url=no }}</ref>在[[葛蘭素史克|葛蘭素史克]]的前身SmithKline Beecham公司於1994年從United Healthcare購入DPS之後，這個部門在SmithKline Beecham的營運發揮出關鍵的作用，到1999年，這個DPS在美國多元化藥物服務所有的會員中，佔比達到44％。<ref name="prnewswire_1999" />快捷藥方於1999年4月收購這個DPS，並將集團本身整合成為[[管理式醫療護理|管理式醫療護理]]組織的產業中一家領先的PBM。<ref name="prnewswire_1999" />

2002年8月，《[[華爾街日報|華爾街日報]]》寫道，雖然PBM在1992年至2002年間"引導醫生開立便宜的藥物，尤其是大型藥廠生產的廉價[[通用名藥物|學名藥]]"，但他們也"靜悄悄地轉向" 銷售昂貴的品牌藥。<ref name="WSJ_2003">{{cite web | url=https://www.wsj.com/articles/SB1029287421439016555 | title=Pharmacy-Benefit Managers at Times Toil for Drug Firms | publisher=The Wall Street Journal | date=August 14, 2002 | accessdate=December 27, 2015 | author=Martinez, Barbara | archive-date=2021-01-16 | archive-url=https://web.archive.org/web/20210116180342/https://www.wsj.com/articles/SB1029287421439016555 | dead-url=no }}</ref>
 
2007年，當CVS藥局收購Caremark這家公司的時候，<ref name=":0" />PBM的功能"從單純地處理處方箋工作，轉到管理醫療保險計劃的藥物福利"，<ref name="Valparaiso_2007" />{{rp|34}} "與藥廠談判藥品的折扣"，<ref name="Valparaiso_2007" />{{rp|34}}並提供"藥物利用審查和[[疾病管理|疾病管理]]"。<ref name="Valparaiso_2007" />{{rp|34}}PBM還建立一種處方集，用來鼓勵甚至要求"醫療計劃參與者使用處方集中首選的藥物來治療疾病"。<ref name="Valparaiso_2007" />{{rp|34}}到2012年，快捷藥方和CVS Caremark已從原來的分級處方集，轉變成只在處方集中單純標明排除不用的特定藥物。<ref name=":0" /><ref>{{cite web|url=http://www.drugchannels.net/2015/08/here-come-2016-pbm-formulary-exclusion.html|title=Drug Channels: Here Come the 2016 PBM Formulary Exclusion Lists!|website=www.drugchannels.net|access-date=2016-03-29|archive-date=2021-01-21|archive-url=https://web.archive.org/web/20210121220659/https://www.drugchannels.net/2015/08/here-come-2016-pbm-formulary-exclusion.html|dead-url=no}}</ref>

==市場與競爭==
截至2004年，[[聯邦貿易委員會|聯邦貿易委員會]]發現PBM是在一個競爭異常激烈的市場中運作。<ref>US Federal Trade Commission & US Department of Justice Antitrust Division, "Improving Health Care:  A Dose of Competition," July 2004</ref>在美國，截至2013年，大部分管理式醫療護理機構的處方藥福利支出，是經由大約60個PBM處理。<ref name="Shepherd_2013">{{cite journal | ssrn=2234212 | title=Is More Information Always Better? Mandatory Disclosure Regulations in the Prescription Drug Market | author=Shepherd, Joanna | journal=Cornell Law Review Online |date=July 2013 | volume=99 |accessdate=}}</ref>少有PBM是獨立組成和運營。PBM在綜合醫療系統（例如凱撒醫院或退伍軍人醫療管理局）內部運作、為零售藥房系統的一部分（例如CVS藥局，或是來愛德）、或者是保險公司的一部分（例如聯合健康集團）。<ref name=":0" /><ref name=":2" />但是到2016年，在美國屬於這個類別的大型PBM公司只剩不到30家，<ref name=":0" />其中三家最大的PBM（快捷藥方、CVS藥局、和聯合健康集團中的OptumRx），它們共同的市場佔有率是78％，為1.8億登記加入者提供藥品保險覆蓋。。<ref name=":0" /><ref name=":3"/>

在2015年，最大的三個上市PBM是快捷藥方，CVS藥局（以前稱為CVS Caremark）和聯合健康集團所屬的OptumRx/Catamaran。<ref>{{cite web |url=https://www.optumrx.com |title=OptumRx |publisher=OptumRx |date= |accessdate=2018-06-20 |archive-date=2016-10-23 |archive-url=https://web.archive.org/web/20161023100034/https://www.optumrx.com/ |dead-url=no }}</ref><ref>{{cite web|url=http://www.prnewswire.com/news-releases/catamaran-shareholders-approve-acquisition-by-unitedhealth-group-515064561.html|title=Catamaran Shareholders Approve Acquisition by UnitedHealth Group|first=|last=Catamaran|website=www.prnewswire.com|access-date=2020-10-10|archive-date=2020-10-24|archive-url=https://web.archive.org/web/20201024225652/https://www.prnewswire.com/news-releases/catamaran-shareholders-approve-acquisition-by-unitedhealth-group-515064561.html|dead-url=no}}</ref><ref>{{cite web|url=https://blogs.wsj.com/briefly/2015/03/30/pharmacy-benefit-managers-the-short-answer/|title=Pharmacy-Benefit Managers – The Short Answer|date=March 30, 2015|publisher=|access-date=2020-10-10|archive-date=2019-09-30|archive-url=https://web.archive.org/web/20190930085048/https://blogs.wsj.com/briefly/2015/03/30/pharmacy-benefit-managers-the-short-answer/|dead-url=no}}</ref>截至2018年，美國三家最大的PBM控制著超過80％的市場。<ref>{{Cite journal|last=Kang|first=So-Yeon|last2=Bai|first2=Ge|last3=DiStefano|first3=Michael J.|last4=Socal|first4=Mariana P.|last5=Yehia|first5=Farah|last6=Anderson|first6=Gerard F.|date=2020-04-02|title=Comparative Approaches to Drug Pricing|url=https://www.annualreviews.org/doi/10.1146/annurev-publhealth-040119-094305|journal=Annual Review of Public Health|language=en|volume=41|issue=1|pages=499–512|doi=10.1146/annurev-publhealth-040119-094305|issn=0163-7525|via=|doi-access=free}}</ref>
 
===快捷藥方===
快捷藥方在2012年以291億美元的價格把競爭對手{{link-en|Medco Health Solutions, Inc.|Medco Health Solutions}}併購，並成為"管理處方藥物福利產業中的強權 "。<ref name="Reuters_2011_07_22">{{cite web | url=https://www.reuters.com/article/2011/07/22/us-expressscripts-idUSTRE76K1GG20110722 | title=Express Scripts takes $14 billion bridge loan | publisher=Reuters | date=July 22, 2011 | accessdate=October 31, 2015 | author=Sierra, Michelle | archive-date=2015-09-14 | archive-url=https://web.archive.org/web/20150914170207/http://www.reuters.com/article/2011/07/22/us-expressscripts-idUSTRE76K1GG20110722 | dead-url=no }}</ref>截至2015年，快捷藥方控股（Express Scripts Holding Company）是美國最大的藥物福利管理組織，<ref name="reuters2015_10_31" />公司在2013年的收入為1,046.2億美元。<ref name=Edgar>{{cite web|url=http://edgar.secdatabase.com/984/119312513063930/filing-main.htm|title=Express Scripts Holding Company FORM 10-K|accessdate=October 31, 2015|date=2013|archive-date=2018-10-05|archive-url=https://web.archive.org/web/20181005111827/http://edgar.secdatabase.com/984/119312513063930/filing-main.htm|dead-url=no}}</ref>
 
2015年10月，快捷藥方開始審查由{{link-en|AbbVie Inc|AbbVie}}和[[梯瓦|梯瓦]]製藥工業兩家公司營運的藥物計劃，這些計劃可能可讓它們規避快捷藥方和其他保險公司對於報銷的限制。這些審查造成對{{link-en|Bausch Health Companies Inc.|Bausch Health}}的合作藥房-Philidor Rx Services的"啟人疑竇的做法"展開調查，<ref name="reuters2015_10_31">{{cite web | url=https://www.reuters.com/article/2015/10/31/us-valeant-pharmacies-expressscripts-exc-idUSKCN0SO2NE20151031 | title=Exclusive: Beyond Valeant, U.S. payers scrutinize other drugmaker ties to pharmacies | publisher=Reuters | date=October 30, 2015 | accessdate=November 1, 2015 | author=Beasley, Deena | location=Los Angeles | archive-date=2015-11-13 | archive-url=https://web.archive.org/web/20151113051801/http://www.reuters.com/article/2015/10/31/us-valeant-pharmacies-expressscripts-exc-idUSKCN0SO2NE20151031 | dead-url=no }}</ref>最後導致Bausch Health Companies Inc.切斷與Philidor Rx Services的往來，而Philidor Rx Services因此中斷營業。<ref>{{Cite web |url=https://www.reuters.com/article/us-valeant-pharmacies-expressscripts-exc-idUSKCN0SO2NE20151031 |title=存档副本 |access-date=2020-10-10 |archive-date=2017-07-22 |archive-url=https://web.archive.org/web/20170722113732/http://www.reuters.com/article/us-valeant-pharmacies-expressscripts-exc-idUSKCN0SO2NE20151031 |dead-url=no }}</ref>
 
===CVS藥局===
1994年，CVS建立藥物福利管理公司-PharmaCare，為雇主、管理式醫療護理組織、保險公司、工會、和政府機構提供涵蓋廣泛的服務。<ref name="CVS-Caremark-Mar-1995-10-K">{{cite web |url=http://edgar.secdatabase.com/1693/89109295000026/filing-main.htm |title=CVS Caremark, Form 10-K, Annual Report, Filing Date Mar 29, 1995 |publisher=secdatabase.com |accessdate=March 29, 2013 |archive-date=2020-11-26 |archive-url=https://web.archive.org/web/20201126150425/http://edgar.secdatabase.com/1693/89109295000026/filing-main.htm |dead-url=no }}</ref>到2002年，CVS的{{link-en|特殊藥品藥房|Specialty pharmacy}}-ProCare（美國"最大的特殊藥品零售/郵購綜合供應商"）<ref name="cvshealth_2001">{{cite web | url=http://investors.cvshealth.com/~/media/Files/C/CVS-IR/reports/cvs-ar-2001.pdf | title=CVS Annual Report | work=CVS | date=2001 | accessdate=October 17, 2015 | archive-date=2016-03-04 | archive-url=https://web.archive.org/web/20160304131937/http://investors.cvshealth.com/~/media/Files/C/CVS-IR/reports/cvs-ar-2001.pdf | dead-url=no }}</ref>{{rp|10}}與他們的藥物福利管理公司-PharmaCare合併。<ref name="cvshealth_2001" /><ref name="imshealth">{{cite web | url=https://www.imshealth.com/deployedfiles/imshealth/Global/North%20America/United%20States/Managed%20Markets/5-29-14%20Specialty_Drug_Trend_Whitepaper_Hi-Res.pdf | title=Overview of the Specialty Drug Trend | work=IMS Health | date=2014 | accessdate=October 5, 2015 | page=11 | archive-date=2015-07-06 | archive-url=https://web.archive.org/web/20150706161023/https://www.imshealth.com/deployedfiles/imshealth/Global/North%20America/United%20States/Managed%20Markets/5-29-14%20Specialty_Drug_Trend_Whitepaper_Hi-Res.pdf | dead-url=no }}</ref>{{rp|4}}Caremark Rx當初是[[百特國際|百特國際]]的子公司，於1992年從百特國際分出，成為一家上市公司。2007年3月，CVS Corporation收購Caremark，成為CVS Caremark，後來更名為CVS藥局（CVS Health）。<ref name="CVS-Caremark-Mar-2007-8-K">{{cite web |url=http://pdf.secdatabase.com/1280/0000950103-07-000726.pdf |title=CVS Caremark, Form 8-K, Current Report, Filing Date Mar 23, 2007 |publisher=secdatabase.com |accessdate=March 29, 2013 |archive-date=2021-01-20 |archive-url=https://web.archive.org/web/20210120120945/http://pdf.secdatabase.com/1280/0000950103-07-000726.pdf |dead-url=no }}</ref>

CVS Caremark在2011年是美國第二大PBM。這家公司在[[田納西州|田納西州]]被提起集體訴訟，訴訟稱CVS Caremark把藥廠的折扣秘密的據為己有，而不是與會員福利計劃共享，並拿昂貴的藥物，而不是價格更便宜的替代品，提供給福利計劃的會員。 CVS Caremark就這項詐欺指控支付2,000萬美元給三個州。<ref name="latimesblogs_2011">{{cite web | url=http://latimesblogs.latimes.com/money_co/2011/12/cvs-caremark-to-pay-20m-to-three-states-over-fraud-allegations.html | title=Money & Company | publisher=Los Angeles Times | date=December 16, 2011 | accessdate=January 17, 2014 | author=Pfeifer, Stuart | archive-date=2020-09-20 | archive-url=https://web.archive.org/web/20200920150918/https://latimesblogs.latimes.com/money_co/2011/12/cvs-caremark-to-pay-20m-to-three-states-over-fraud-allegations.html | dead-url=no }}</ref>

===聯合健康集團 ===
Optum是聯合健康集團下屬的醫療衛生服務體系，Optum旗下的OptumRx，一直是美國領先的PBM。<ref name="Optum_2012">{{citation |title=New Optum Product Helps Companies Better Manage Pharmacy Costs |url=http://www.unitedhealthgroup.com/newsroom/articles/news/optum/2012/1018protectrx.aspx |location=Irvine, California |date=October 18, 2012 |accessdate=October 31, 2015 |archive-url=https://web.archive.org/web/20180620074252/http://www.unitedhealthgroup.com/newsroom/articles/news/optum/2012/1018protectrx.aspx |archive-date=2018-06-20 |dead-url=no }}</ref>

2015年3月，聯合健康集團以約128億美元的價格收購{{link-en|Catamaran Corporation|Catamaran Corporation}}，把PBM的業務進一步拓展。<ref name="Forbes_2015_April">{{cite web | url=https://www.forbes.com/sites/greatspeculations/2015/04/01/what-the-unitedhealth-catamaran-deal-means-for-walgreens/ | title=What The UnitedHealth-Catamaran Deal Means For Walgreens | publisher=Forbes | date=April 1, 2015 | accessdate=October 31, 2015 | author=Trefis Team | archive-date=2020-10-13 | archive-url=https://web.archive.org/web/20201013025254/https://www.forbes.com/sites/greatspeculations/2015/04/01/what-the-unitedhealth-catamaran-deal-means-for-walgreens/ | dead-url=no }}</ref><ref name="WSJ_2015_Mar_30">{{cite web | url=https://blogs.wsj.com/briefly/2015/03/30/pharmacy-benefit-managers-the-short-answer/ | title=The Short Answer: Pharmacy-Benefit Managers | publisher=The Wall Street Journal | date=March 30, 2015 | accessdate=October 31, 2015 | archive-date=2019-09-30 | archive-url=https://web.archive.org/web/20190930085048/https://blogs.wsj.com/briefly/2015/03/30/pharmacy-benefit-managers-the-short-answer/ | dead-url=no }}</ref>

==倡議和遊說==
許多藥物福利管理者組成{{link-en|藥物照護管理協會|Pharmaceutical Care Management Association}}，作為這個產業的共同代表。
 
===生物相似藥===
{{main|生物相似藥}}

PBM一直堅定的支持建立[[美國食品藥品監督管理局|美國食品藥品監督管理局]]（FDA）的途徑，以促進生物相似藥-價格昂貴的[[美國特殊藥品|特殊藥品]]（治療[[阿爾茨海默病|阿爾茨海默病]]、[[類風濕性關節炎|類風濕性關節炎]]、和[[多發性硬化症|多發性硬化症]]）的核准。<ref name="lobbyists_2009">{{citation |author=Schouten, F. |title=Lobbyists battle over drug sales |work=USA Today |date=July 29, 2009 |url=https://abcnews.go.com/Business/story?id=8197972 |accessdate=October 31, 2015 |archive-date=2021-01-28 |archive-url=https://web.archive.org/web/20210128033845/https://abcnews.go.com/Business/story?id=8197972 |dead-url=no }}</ref>PBM支持所謂的生物相似藥立法，這項法案並未授予品牌藥藥廠壟斷定價權力。<ref name="USA_Today_2009_seek">{{citation |url=http://usatoday30.usatoday.com/printedition/news/20090812/editorial12_st.art.htm |title=Our view on generic medications: Drugmakers seek excessive monopolies on ‘biologics’ |work=USA Today |date=August 12, 2009 |accessdate=October 31, 2015 |archive-date=2020-10-09 |archive-url=https://web.archive.org/web/20201009200946/http://usatoday30.usatoday.com/printedition/news/20090812/editorial12_st.art.htm |dead-url=no }}</ref> 2015年，聯邦貿易委員會發現生物製品的專利能為創新提供足夠的動力，而且獨佔期的延長"不會引發新的生物藥或{{link-en|適應症|Indication (medicine)}}的產生"，而"損害"到法案能產生的利益。.<ref name="FTC_2009">{{citation |work=Federal Trade Commission |url=https://www.ftc.gov/news-events/press-releases/2009/06/ftc-releases-report-follow-biologic-drug-competition |title=Follow-on Biologic Drug Competition |date=June 2009 |accessdate=October 31, 2015 |archive-date=2021-03-25 |archive-url=https://web.archive.org/web/20210325003704/https://www.ftc.gov/news-events/press-releases/2009/06/ftc-releases-report-follow-biologic-drug-competition |dead-url=no }}</ref>

==爭議和訴訟==
*1998年，[[美國司法部|美國司法部]]聯邦檢察官詹姆斯·希恩（James Sheehan）對PBM展開調查，針對這個產業是否能有效降低處方藥成本和節省客戶費用方面，提出質疑。<ref name="cga_gov_2003" />
 
*2004年，訴訟事件為PBM的作為增加不確定性。<ref name="latimesblogs_2011" /><ref name="Reasonable_Rx_2008">{{cite book|title = Reasonable Rx: Solving the Drug Price Crisis|author1 = Stan Finkelstein|author2 = Peter Temin|work = FT Press|location = Upper Saddle River, New Jersey, USA|date = 2008|page = [https://archive.org/details/reasonablerxsolv00fink/page/208 208]|isbn = 978-0-132344494|url-access = registration|url = https://archive.org/details/reasonablerxsolv00fink/page/208}}</ref> 2015年，針對PBM所涉及的詐欺、騙術、或[[競爭法|反托拉斯法]]行為，共有七項法律訴訟被提出。<ref name=":0" /><ref name=":3" />

*州立法機關一直使用"透明度"、"信任"、和"披露"條款來改進PBM的商業做法。<ref name="Reasonable_Rx_2008" /> 在2011年，密西西比州藥房委員會（Mississippi Board of Pharmacy）成立一個藥物福利管理者的新部門，任務是核准以及規範PBM。<ref name="MBP_2012">{{citation |url=http://www.mbp.state.ms.us/mbop/Pharmacy.nsf/webpageedit/Newsletter_2012_aprilnews/$FILE/March%202012%20(Autosaved).pdf?OpenElement |work=Mississippi Board of Pharmacy |location=Madison, MS |date=April 2012 |accessdate=October 31, 2015 |title=Newsletter |archive-date=2016-03-05 |archive-url=https://web.archive.org/web/20160305120513/http://www.mbp.state.ms.us/mbop/Pharmacy.nsf/webpageedit/Newsletter_2012_aprilnews/$FILE/March%202012%20(Autosaved).pdf?OpenElement |dead-url=no }}</ref>

*2013年，{{link-en|聯邦醫療保險和聯邦醫療補助服務中心|Centers for Medicare & Medicaid Services}}（CMS）所做的一項研究發現，郵購藥房與PBM的議定價格比社區藥房的議定價格高出83％。<ref>{{cite web |url=http://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovGenIn/Downloads/Negotiated-Pricing-Between-General-Mail-Order-and-Retail-PharmaciesDec92013.pdf |title=Article |website=www.cms.gov |format=PDF |access-date=2020-10-10 |archive-date=2021-04-15 |archive-url=https://web.archive.org/web/20210415231747/https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovGenIn/Downloads/Negotiated-Pricing-Between-General-Mail-Order-and-Retail-PharmaciesDec92013.pdf |dead-url=no }}</ref>
 
*在2014年的ERISA（《{{link-en|1974年僱員退休所得安全法|Employee Retirement Income Security Act of 1974}}》）一項聽證會中指出，[[垂直整合|垂直整合]]後的PBM有構成[[利益衝突|利益衝突]]的可能，並且PBM的醫療保險計劃贊助人（例如藥廠）"在…確定是否遵守PBM合同（包括直接和間接補償條款）的時候，碰到極大的困難。"。<ref>{{cite web|url=http://www.dol.gov/ebsa/publications/2014ACreport1.html|title=PBM Compensation and Fee Disclosure|website=www.dol.gov|access-date=2016-03-29|archive-date=2016-08-17|archive-url=https://web.archive.org/web/20160817002924/https://www.dol.gov/ebsa/publications/2014ACreport1.html|dead-url=no}}</ref>
 
*2017年，《[[洛杉磯時報|洛杉磯時報]]》寫道，PBM導致藥品成本上漲，尤其是對[[糖尿病|糖尿病]]類的藥物。<ref>{{cite web|url=http://www.latimes.com/business/hiltzik/la-fi-hiltzik-pbm-drugs-20170611-story.html|title=How 'price-cutting' middlemen are making crucial drugs vastly more expensive|first=Michael|last=Hiltzik|website=latimes.com|access-date=2020-10-10|archive-date=2021-02-26|archive-url=https://web.archive.org/web/20210226062236/https://www.latimes.com/business/hiltzik/la-fi-hiltzik-pbm-drugs-20170611-story.html|dead-url=no}}</ref>
 
*[[美國衛生和公共服務部|美國衛生和公共服務部]]部長[[亞歷克斯·阿扎|亞歷克斯·阿扎]]說起有關PBM時表示："定價上漲時，每個人都會獲利，唯獨患者是例外。這是一個隨著時間發展而成的驚人以及詭異的系統。"<ref>{{cite web | title=Do prescription drug middlemen help keep prices high? | website=PBS NewsHour | date=August 11, 2018 | url=https://www.pbs.org/newshour/show/do-prescription-drug-middlemen-help-keep-prices-high | access-date=August 12, 2018 | archive-date=2021-05-03 | archive-url=https://web.archive.org/web/20210503183932/https://www.pbs.org/newshour/show/do-prescription-drug-middlemen-help-keep-prices-high | dead-url=no }}</ref>

*2019年1月31日，衛生與公共服務部發布一項擬議規則，以將《{{link-en|反回扣法規|Anti-Kickback Statute}}》取消，這項法規允許PBM從藥廠收取回扣，是PBM和其他計劃贊助人的保護傘，。<ref>{{Cite web|url=https://www.federalregister.gov/documents/2019/02/06/2019-01026/fraud-and-abuse-removal-of-safe-harbor-protection-for-rebates-involving-prescription-pharmaceuticals|title=Public Inspection: Fraud and Abuse: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees|website=Federal Register|access-date=2019-01-31|archive-date=2021-03-30|archive-url=https://web.archive.org/web/20210330150036/https://www.federalregister.gov/documents/2019/02/06/2019-01026/fraud-and-abuse-removal-of-safe-harbor-protection-for-rebates-involving-prescription-pharmaceuticals|dead-url=no}}</ref>
 
*參議員[[榮恩·魏登|榮恩·魏登]]（民主黨籍）在2019年4月表示，它們“就像那種會剝削客戶的中間人一樣”，因為當他們靠選擇高價藥物而不選低價藥物，就能從中賺到大錢。<ref>{{cite news |title=Pharmacy benefit managers face bipartisan criticism |url=https://www.ft.com/content/a65d6fcc-5ade-11e9-939a-341f5ada9d40?emailId=5cb5b2e8cb13dd000473388e |accessdate=4 June 2019 |publisher=Financial Times |date=9 April 2019 |archive-date=2020-09-26 |archive-url=https://web.archive.org/web/20200926025121/https://www.ft.com/content/a65d6fcc-5ade-11e9-939a-341f5ada9d40?emailId=5cb5b2e8cb13dd000473388e |dead-url=no }}</ref>

==參見==
{{div col|colwidth=25em}}
*[[網路藥房|網路藥房]]
*[[首選藥房網絡|首選藥房網絡]]
*[[聯邦醫療保險D部分|聯邦醫療保險D部分]]
*{{link-en|Medicare D部分覆蓋缺口|Medicare Part D coverage gap}}
*[[聯邦醫療保險|聯邦醫療保險]]
*[[聯邦醫療補助|聯邦醫療補助]]
*[[患者保護與平價醫療法案|患者保護與平價醫療法案]]
*[[自負額_(醫療保險)|自負額 (醫療保險)]]
*[[共付額|共付額]]
*[[自付費用|自付費用]]
*[[共同保險|共同保險]]
*[[管理式醫療護理|管理式醫療護理]]
*[[健康維護組織|健康維護組織]]
*[[醫療保險|醫療保險]]
*[[美國的醫療保險|美國的醫療保險]]
*[[美國的處方藥價格|美國的處方藥價格]]
*[[藥物成本|藥物成本]]
*[[處方藥|處方藥]]
*[[通用名藥物|學名藥]]
*[[孤兒藥|孤兒藥]]
{{div col end}}

==參考文獻==
{{reflist|2}}

==外部連結==
* [https://www.pbmi.com/pbmdirectory Pharmacy Benefit Management Institute list of PBM companies] {{Wayback|url=https://www.pbmi.com/pbmdirectory |date=20171107014903 }}

[[Category:美国公司|Category:美国公司]]
[[Category:藥學|Category:藥學]]